Mrs Jennifer Down

Clinical Medicine, School of Medicine and Population Health

Research Associate

j.m.down@sheffield.ac.uk
+44 114 215 9209

Full contact details

Mrs Jennifer Down
Clinical Medicine, School of Medicine and Population Health
EU25, E Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Publications

Show: Featured publications All publications

Journal articles

All publications

Journal articles

Conference proceedings papers

  • Stewart G, Tazzyman ST, Lath D, Down J, Lawson M, Muthana M & Chantry A (2019) Myeloma-specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 97-97) RIS download Bibtex download
  • Jiang Y, Down J, Raffles S, Jenkins E, Ferretti L, Bunce C, Drayson M, Lawson M & Khanim F (2018) Targeting free light chain (FLC) secretion and the unfolded protein response in myeloma cells using VaN, a combination of repurposed drugs. Experimental Hematology, Vol. 64(Suppl) (pp S74-S75). Los Angeles, USA, 23 August 2018 - 26 August 2018. View this article in WRRO RIS download Bibtex download
  • Pesce* G, Glen A, Lippitt J, Fowles A, Rehman I & Eaton CL (2011) Spontaneous fusion between prostate cancer cells: A driver for development of tumor heterogeneity and growth in bone. Bone, Vol. 48(1) (pp S46-S47) RIS download Bibtex download
  • Cross NA, Papageorgiou M, Lippitt J, Nyambo R, Hamdy FC & Eaton CL (2007) Bone marrow stromal cell-derived insulin-like growth factor (IGF) II enhances growth and survival of prostate cancer cells and potentiates androgen action. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 88(6) (pp A94-A94) RIS download Bibtex download
  • Cross SS, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR & Holen I (2005) There is a general loss of expression of receptor activator of nFkB ligand (RANKL) in human breast cancers but retention of expression has a significant negative association with expression of oestrogen receptor (ER). JOURNAL OF PATHOLOGY, Vol. 207 (pp 27-27) RIS download Bibtex download
  • Cross SS, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR & Holen I (2005) Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) is expressed in human breast cancers and has a significant negative association with tumours with poor prognosis.. JOURNAL OF PATHOLOGY, Vol. 207 (pp 27-27) RIS download Bibtex download
  • Cross SS, Hollingbury FE, Lippitt JM, Evans CA, Balasubramanian SP, Reed MWR, Handy FC & Winder SJ (2005) Loss of intercellular expression of beta-dystroglycan is a common event in breast cancer. JOURNAL OF PATHOLOGY, Vol. 205 (pp 8-8) RIS download Bibtex download
  • Cross SS, Hollingbury FE, Lippitt JM, Feeley KM, Azzouzi AR, Winder SJ & Hamdy FC (2005) Loss of intercellular expression of beta-dystroglycan is a common event in prostate cancer and is significantly associated with loss of differentiation. JOURNAL OF PATHOLOGY, Vol. 205 (pp 15-15) RIS download Bibtex download
  • Cross SS, Hollingbury FE, Lippitt JM, Catto JW, Hamdy EC & Winder SJ (2005) beta-dystroglycan is constitutively expressed at the intercellular junctions of epithelial cells and this expression is frequently absent in common cancers. JOURNAL OF PATHOLOGY, Vol. 205 (pp 6-6) RIS download Bibtex download
  • Papageorgiou M, Lippitt J, Nyambo R, Cross N, Hamdy FC & Eaton CL (2005) Human bone marrow stromal cell derived IGF signaling enhances PSA production as well as proliferation/survival of androgen sensitive prostate cancer cells in vitro. CANCER TREATMENT REVIEWS, Vol. 31 (pp S36-S36) RIS download Bibtex download
  • Ashcroft AJ, Cruickshank SM, Croucher PI, Perry MJ, Rollinson S, Lippitt JM, Child JA, Dunstan CR, Carding SR & Morgan GJ (2004) T-cell-mediated colitis and bone destruction in a murine model of autoimmunity are both driven by RANK/RANK LIGAND interactions and modulated by recombinant Fc-OPG. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 125 (pp 67-67) RIS download Bibtex download
  • Van Poznac C, Cross SS, Saggese M, Lippitt JM, Hudis C, Coleman RE & Holen I (2004) Human breast cancers express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and receptor activator of nFkB ligand (RANKL). BONE, Vol. 34 (pp S29-S29) RIS download Bibtex download
  • Ashcroft AJ, Cruickshank SM, Croucher PI, Perry MJ, Lippitt JM, Child JA, Dunstan C, Carding SR & Morgan GM (2003) T cell mediated colitis and bone destruction are driven by RANK/RANK LIGAND interactions and can be modulated by recombinant Fc-OPG.. BLOOD, Vol. 102(11) (pp 528A-528A) RIS download Bibtex download
  • Naylor KE, Rogers A, Smith C, Hall V, Fraser RB, Holen I, Lippitt J, Eastell R & Blumsohn A (2003) Source of maternal serum osteoprotegerin during human pregnancy. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18(7) (pp 1376-1376) RIS download Bibtex download
  • Holen I, Wells JM, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Jagdev SP, Hamdy FC & Eaton CL (2002) The role of osteoprotegerin in breast and prostate cancer. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 17(7) (pp 1339-1339) RIS download Bibtex download
  • Holen I, Croucher PI, Evans AC, Lippitt JM, Hamdy FC, Coleman RE & Eaton CL (2002) OPG is a survival factor for breast- and prostate cancer cells in vitro. BONE, Vol. 30(3) (pp 28S-28S) RIS download Bibtex download

Preprints